American Century Companies Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

American Century Companies Inc. reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,902,432 shares of the biopharmaceutical company’s stock after selling 2,225 shares during the period. American Century Companies Inc. owned about 1.31% of Amicus Therapeutics worth $36,761,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $55,000. R Squared Ltd purchased a new stake in Amicus Therapeutics in the fourth quarter worth about $79,000. KBC Group NV raised its stake in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 3,120 shares during the period. Sciencast Management LP purchased a new position in shares of Amicus Therapeutics during the 4th quarter valued at about $100,000. Finally, Stephens Inc. AR bought a new position in shares of Amicus Therapeutics during the 4th quarter valued at approximately $101,000.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on FOLD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Finally, Wells Fargo & Company cut their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $8.59 on Friday. The company has a market cap of $2.64 billion, a price-to-earnings ratio of -47.72, a PEG ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1 year low of $8.40 and a 1 year high of $12.65. The stock’s 50 day simple moving average is $9.30 and its two-hundred day simple moving average is $9.99. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.